Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GlaxoSmithKline ( (GB:GSK) ) just unveiled an update.
GSK has secured Japanese approval for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe or refractory bronchial asthma and chronic rhinosinusitis with nasal polyps, adding to prior clearances in the US and UK and a positive regulatory opinion in the EU. Based on phase III SWIFT and ANCHOR data showing that twice-yearly dosing significantly reduced asthma exacerbations and improved nasal polyp size and nasal obstruction while maintaining a placebo-like safety profile, the therapy offers a convenient, durable option that could ease disease burden for patients and lower strain on healthcare systems, bolstering GSK’s competitive position in high-value respiratory biologics.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £17.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall stock score is driven by strong financial performance and favorable valuation metrics. The company’s strategic initiatives, including share buybacks and R&D investments, support its growth outlook. However, challenges in cash flow and certain market segments warrant cautious optimism.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GSK is a global biopharmaceutical company with a long-established, industry-leading respiratory portfolio and pipeline spanning vaccines, targeted biologics and inhaled medicines. The company focuses on improving outcomes for patients with asthma, COPD and other respiratory and inflammatory diseases by developing next-generation standards of care that aim to modify underlying disease mechanisms and prevent progression.
Average Trading Volume: 8,286,325
Technical Sentiment Signal: Buy
Current Market Cap: £73.89B
Find detailed analytics on GSK stock on TipRanks’ Stock Analysis page.